GKOS (Glaukos) Ending Cash Position: $108.1 Mil (As of Mar. 2026)

What is Glaukos Ending Cash Position?

Glaukos GKOS +1.31% 80 Ending Cash Position is $108.1 Mil as of Mar. 2026. GuruFocus rates GKOS with a GF Score™ of 80/100 and a GF Value™ of $136.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Glaukos's Ending Cash Position for the quarter that ended in Mar. 2026 was $108.1 Mil.

Glaukos's quarterly Ending Cash Position declined from Sep. 2025 ($102.1 Mil) to Dec. 2025 ($94.6 Mil) but then increased from Dec. 2025 ($94.6 Mil) to Mar. 2026 ($108.1 Mil).

Glaukos's annual Ending Cash Position increased from Dec. 2023 ($99.3 Mil) to Dec. 2024 ($174.4 Mil) but then declined from Dec. 2024 ($174.4 Mil) to Dec. 2025 ($94.6 Mil).

Glaukos Ending Cash Position Related Terms

Glaukos Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Glaukos's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glaukos Ending Cash Position Chart

Glaukos Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Ending Cash Position

Get a 7-Day Free Trial

110.12

126.60

99.32

174.36

94.65

Glaukos Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Ending Cash Position	Get a 7-Day Free Trial															118.99	104.65	102.08	94.65	108.08

80GF Score

Glaukos Corp GKOS

Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Glaukos Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Glaukos's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	174.359	+	-79.712
	=	94.6

Glaukos's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	94.647	+	13.436
	=	108.1

Frequently Asked Questions Learn more about Ending Cash Position →

What does a Ending Cash Position of $108.1 Mil mean?

Glaukos (GKOS) has a Ending Cash Position of $108.1 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Glaukos and its competitors.

Is Glaukos' Ending Cash Position too high?

Glaukos' current Ending Cash Position is $108.1 Mil. Overall, Glaukos has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Glaukos' Ending Cash Position compare to BIO and BRKR?

Glaukos' Ending Cash Position of $108.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Ending Cash Position for a Medical Devices & Instruments company?

A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Ending Cash Position mean?

A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Glaukos and its competitors. Glaukos's current Ending Cash Position is $108.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Glaukos stock overvalued right now?

Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $136.24, compared to a current price of $150.65 — trading 10.6% above its estimated fair value. The current Ending Cash Position is $108.1 Mil. Glaukos' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Ending Cash Position calculated?

Ending Cash Position is calculated from a company's financial statements. For Glaukos (GKOS), the current Ending Cash Position is $108.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (GKOS) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of $150.65 is trading 10.6% above its estimated GF Value™ of $136.24. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for GKOS:

Ending Cash Position: $108.1 Mil
GF Value™: $136.24 vs. price of $150.65 (10.6% above fair value)
GF Score™: 80/100 with 6 warning signs

No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies BIO BRKR PODD GMED LIVN PEN IRTC HAE ITGR ESTA ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges 6GJ:Germany

Address One Glaukos Way, Aliso Viejo, CA, USA, 92656

Website https://www.glaukos.com

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

80GF Score

Get the complete analysis for GKOS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$150.65

Price

$136.24

GF Value

View GKOS Analysis

See Ending Cash Position data for all stocks →